NCT02696356View on ClinicalTrials.gov

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Melanoma
Interventions
BIOLOGICAL

GRN-1201

GRN-1201 is a vaccine comprised of 4 peptides

Trial Locations (4)

15232

University of Pittsburg, Pittsburgh

45219

The Christ Hospital Cancer Research, Cincinnati

84112

Huntsman Cancer Institute, Salt Lake City

97213

Providence Health and Services, Providence Portland Medical Center, Portland

Sponsors
All Listed Sponsors
lead

BrightPath Biotherapeutics

INDUSTRY